DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR FAMCICLOVIR
Clinical Trials for Famciclovir
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00098046 | Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection | Completed | Novartis | Phase 3 | Varicella zoster virus causes chickenpox in children and shingles in adults. Chickenpox is usually a self-limiting illness characterized by fever and a rash. Serious complications can include secondary bacterial infections, pneumonia, and encephalitis. Anti-viral treatment is not a standard of care in immunocompetent children, but is recommended whenever a risk of complication exists. This study will evaluate the safety and blood levels of a new formulation of famciclovir in children 1-12 years of age. |
| NCT00098059 | Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection | Completed | Novartis Pharmaceuticals | Phase 3 | This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir (12.5 mg/kg) to assess pharmacokinetics (PK) and safety. In Part B, patients will receive multiple doses of famciclovir alone or with concomitant oral anti-herpes therapy to assess safety and tolerability. Part B will start only after PK data from Part A had been analyzed. |
| NCT00129818 | A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding | Completed | Novartis | Phase 4 | The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity. |
| NCT00171990 | Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes | Completed | Novartis | Phase 3 | This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Famciclovir
Condition Name
Clinical Trial Locations for Famciclovir
Trials by Country
Clinical Trial Progress for Famciclovir
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Famciclovir
Sponsor Name
